The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania
Subscribe To Our Newsletter & Stay Updated
